Bay Area's BioTrace Medical Nabs FDA Clearance of Innovative Temporary Pacing Technology for the Heart

Tempo^® Temporary Pacing Lead Designed to Reduce Complications and Hospital Length of Stay;

First-In-Human Clinical Data to be Presented at TCT 2016

SAN CARLOS, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s Tempo^® Lead, an innovative temporary pacing lead designed for use in procedures in which temporary pacing is indicated, including transcatheter aortic valve replacement (TAVR) and electrophysiology (EP) procedures.

“FDA clearance is an exciting milestone for BioTrace”

Temporary leads are used in more than 350,000 procedures each year, a number that is growing rapidly as the population ages and TAVR becomes increasingly common. The temporary pacing lead, a small catheter with two electrodes, is placed in the right ventricle of the heart through a vein in the groin or neck. The lead is then connected to an external pacemaker allowing a physician to monitor and control a patient’s heart rate for up to several days.

The design of conventional temporary pacing leads can cause serious complications. Current temporary leads can be easily dislodged from the heart, which may result in loss of pacing, with serious consequences for the patient. As a result, patients are often limited to bed rest for the duration of temporary pacing lead placement, delaying ambulation and thereby increasing length of stay in costly hospital units such as intensive care. In addition, current leads risk perforation of the heart wall, which may lead to pericardial effusion and tamponade, in which blood from within the heart escapes into the sac surrounding the heart, leading to potentially life-threatening cardiac compression.

BioTrace Medical’s Tempo Lead incorporates innovations designed for secure and stable cardiac pacing with the goal of reducing complications and allowing patients to ambulate sooner after procedures. The Tempo Lead features a novel active fixation mechanism, bipolar electrodes and a soft tip. An elastomeric balloon may be inflated to aid passage of the lead through the venous vasculature and into the right ventricle, and aids in orienting the lead.

“The Tempo Lead represents the first major advance in temporary pacing since the technology was introduced decades ago,” said Dr. Susheel Kodali, director of the Heart Valve Program at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York. “As a critical component of every TAVR procedure, temporary leads are integral to successful clinical outcomes for patients. I am excited about the potential of this technology and look forward to using it in my practice.”

Results of the first-in-human study of the technology will be presented at the annual Transcatheter Cardiac Therapeutics (TCT) conference in Washington, D.C. on Sunday, Oct. 30, at 10:59am in Room 209, Level 2.

“FDA clearance is an exciting milestone for BioTrace,” said Laura Dietch, CEO of BioTrace Medical. “We are pleased to bring this important innovation to the significant and growing number of patients needing better temporary pacing options to minimize risks and life-threatening complications. We look forward to launching in select U.S. centers in the coming weeks.”

About BioTrace Medical

BioTrace Medical, Inc., a venture backed company based in San Carlos, Calif., is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. For more information, visit www.biotracemedical.com.